HIF2A is Associated with Improved Survival in Acute Myeloid Leukemia (AML) Patients
Publication
, Conference
Lee, KL; Iqbal, J; Wong, GC; Ong, ST
Published in: LABORATORY INVESTIGATION
2023
Duke Scholars
Published In
LABORATORY INVESTIGATION
EISSN
1530-0307
ISSN
0023-6837
Publication Date
2023
Volume
103
Issue
3
Start / End Page
S1180 / S1181
Related Subject Headings
- Pathology
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Lee, K. L., Iqbal, J., Wong, G. C., & Ong, S. T. (2023). HIF2A is Associated with Improved Survival in Acute Myeloid Leukemia (AML) Patients. In LABORATORY INVESTIGATION (Vol. 103, pp. S1180–S1181).
Lee, Kian Leong, Jabed Iqbal, Gee Chuan Wong, and Sin Tiong Ong. “HIF2A is Associated with Improved Survival in Acute Myeloid Leukemia (AML) Patients.” In LABORATORY INVESTIGATION, 103:S1180–81, 2023.
Lee KL, Iqbal J, Wong GC, Ong ST. HIF2A is Associated with Improved Survival in Acute Myeloid Leukemia (AML) Patients. In: LABORATORY INVESTIGATION. 2023. p. S1180–1.
Lee, Kian Leong, et al. “HIF2A is Associated with Improved Survival in Acute Myeloid Leukemia (AML) Patients.” LABORATORY INVESTIGATION, vol. 103, no. 3, 2023, pp. S1180–81.
Lee KL, Iqbal J, Wong GC, Ong ST. HIF2A is Associated with Improved Survival in Acute Myeloid Leukemia (AML) Patients. LABORATORY INVESTIGATION. 2023. p. S1180–S1181.
Published In
LABORATORY INVESTIGATION
EISSN
1530-0307
ISSN
0023-6837
Publication Date
2023
Volume
103
Issue
3
Start / End Page
S1180 / S1181
Related Subject Headings
- Pathology
- 3202 Clinical sciences
- 1103 Clinical Sciences